A Director at Dynavax (DVAX) is Buying Shares
Yesterday, a Director at Dynavax (DVAX), Peggy Phillips, bought shares of DVAX for $50K.
Following this transaction Peggy Phillips’ holding in the company was increased by 120.75% to a total of $102.4K. In addition to Peggy Phillips, 2 other DVAX executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on Dynavax’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $8.3 million and GAAP net loss of $42.71 million. In comparison, last year the company earned revenue of $1.25 million and had a GAAP net loss of $39.44 million. Currently, Dynavax has an average volume of 2.31M. The Company has a Price to Book ratio of 20.6757.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $16.00, reflecting a 376.2% upside. Starting in October 2018, DVAX received 23 Buy ratings in a row. Four different firms, including Cantor Fitzgerald and Cowen & Co., currently also have a Buy rating on the stock.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body’s innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases.